Login to Your Account

Other News To Note

Tuesday, August 16, 2011
• Lpath Inc., of San Diego, said the National Institutes of Health's Type I Diabetes Preclinical Testing Program will provide financial support for the further study of Lpathomab's efficacy in animal models of the disease, particularly diabetic neuropathy. The award will provide NIH contract resources to conduct in vivo studies of the monoclonal antibody in rats.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription